Researchers recently found that use of osteoporosis medication in older adults after hip fracture, which is recommended by most guidelines, reduced subsequent nonvertebral fractures.
These are the first osteoporosis recommendations to outline the best course of clinical care for adults aged 65 years and older with hip or vertebral fracture.
The RANKL inhibitor denosumab is superior to the bisphosphonate risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomized controlled study.
Partial or total thyroidectomy may increase the long-term risk of osteoporosis and osteoporotic fracture, especially for younger patients and women, according to a recent large study.
Patients on long-term steroids for dermatologic indications are often not evaluated for glucocorticoid-induced osteoporosis (GIOP), new single-center research suggests.